{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:26:58Z","timestamp":1765758418460,"version":"build-2065373602"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.rdc.2015.08.010","type":"journal-article","created":{"date-parts":[[2015,10,26]],"date-time":"2015-10-26T19:13:42Z","timestamp":1445886822000},"page":"91-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Corticosteroids in Antineutrophil Cytoplasmic Antibody\u2013Associated Vasculitis"],"prefix":"10.1016","volume":"42","author":[{"given":"Sarah F.","family":"Keller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eli M.","family":"Miloslavsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.rdc.2015.08.010_bib1","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1056\/NEJM199711203372106","article-title":"Small-vessel vasculitis","volume":"337","author":"Jennette","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.rdc.2015.08.010_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rdc.2014.09.003","article-title":"Current landscape of antineutrophil cytoplasmic antibody-associated vasculitis: classification, diagnosis, and treatment","volume":"41","author":"Lally","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"issue":"5","key":"10.1016\/j.rdc.2015.08.010_bib3","first-page":"788","article-title":"Therapy of vasculitis","volume":"21","author":"Bacon","year":"1994","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2015.08.010_bib4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJM197908023010503","article-title":"Cyclophosphamide therapy of severe systemic necrotizing vasculitis","volume":"301","author":"Fauci","year":"1979","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.rdc.2015.08.010_bib5","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1288\/00005537-195104000-00004","article-title":"Idiopathic (lethal) granuloma of the midline facial tissues treated with cortisone: report of a case","volume":"61","author":"Moore","year":"1951","journal-title":"Laryngoscope"},{"issue":"5091","key":"10.1016\/j.rdc.2015.08.010_bib6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/bmj.2.5091.265","article-title":"Giant-cell granuloma of the respiratory tract (Wegener\u2019s granulomatosis)","volume":"2","author":"Walton","year":"1958","journal-title":"Br Med J"},{"issue":"27","key":"10.1016\/j.rdc.2015.08.010_bib7","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM197112302852701","article-title":"Effect of cyclophosphamide upon the immune response in Wegener\u2019s granulomatosis","volume":"285","author":"Fauci","year":"1971","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.rdc.2015.08.010_bib8","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2015.08.010_bib9","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-98-1-76","article-title":"Wegener\u2019s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years","volume":"98","author":"Fauci","year":"1983","journal-title":"Ann Intern Med"},{"issue":"16","key":"10.1016\/j.rdc.2015.08.010_bib10","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","article-title":"Antiinflammatory action of glucocorticoids\u2013new mechanisms for old drugs","volume":"353","author":"Rhen","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.rdc.2015.08.010_bib11","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/ard.2006.062711","article-title":"EULAR recommendations for conducting clinical studies and\/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"66","author":"Hellmich","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"6 Suppl 43","key":"10.1016\/j.rdc.2015.08.010_bib12","article-title":"Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis","volume":"24","author":"Mukhtyar","year":"2006","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2015.08.010_bib13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00005792-199601000-00003","article-title":"Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients","volume":"75","author":"Guillevin","year":"1996","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.rdc.2015.08.010_bib14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.rdc.2015.08.010_bib15","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener\u2019s granulomatosis","volume":"352","author":"Wegener's Granulomatosis Etanercept Trial (WGET) Research Group","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.rdc.2015.08.010_bib16","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0197-2456(02)00209-X","article-title":"Design of the Wegener\u2019s Granulomatosis Etanercept Trial (WGET)","volume":"23","author":"WGET Research Group","year":"2002","journal-title":"Control Clin Trials"},{"issue":"8","key":"10.1016\/j.rdc.2015.08.010_bib17","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1002\/art.11075","article-title":"Limited versus severe Wegener\u2019s granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial","volume":"48","author":"Stone","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2015.08.010_bib18","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000167998","article-title":"Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis","volume":"9","author":"Bolton","year":"1989","journal-title":"Am J Nephrol"},{"issue":"7","key":"10.1016\/j.rdc.2015.08.010_bib19","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.rdc.2015.08.010_bib20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.rdc.2015.08.010_bib21","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.rdc.2015.08.010_bib22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.rdc.2015.08.010_bib23","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.rdc.2015.08.010_bib24","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.rdc.2015.08.010_bib25","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"De Groot","year":"2009","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.rdc.2015.08.010_bib26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A\u00a0randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.rdc.2015.08.010_bib27","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1002\/art.22163","article-title":"Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial","volume":"54","author":"Mazlumzadeh","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2015.08.010_bib28","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/art.39104","article-title":"Outcomes of non-severe relapses in ANCA-associated vasculitis treated with glucocorticoids","volume":"67","author":"Miloslavsky","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2015.08.010_bib29","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/1529-0131(199904)42:4<780::AID-ANR23>3.0.CO;2-M","article-title":"Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality","volume":"42","author":"Ward","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2015.08.010_bib30","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1471-2334-4-42","article-title":"Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention","volume":"4","author":"Sowden","year":"2004","journal-title":"BMC Infect Dis"},{"issue":"2","key":"10.1016\/j.rdc.2015.08.010_bib31","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2215\/CJN.05610611","article-title":"Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease","volume":"7","author":"McGregor","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.rdc.2015.08.010_bib32","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/art.39011","article-title":"Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy","volume":"67","author":"Pagnoux","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.rdc.2015.08.010_bib33","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/acr.20176","article-title":"Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis","volume":"62","author":"Walsh","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"year":"2000","series-title":"The Assessment of Prednisone in Remission trial\u2014center of excellence approach (TAPIR)","author":"Merkel","key":"10.1016\/j.rdc.2015.08.010_bib34"},{"issue":"2","key":"10.1016\/j.rdc.2015.08.010_bib35","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/art.38210","article-title":"Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis","volume":"66","author":"del Rinc\u00f3n","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2015.08.010_bib36","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1136\/annrheumdis-2011-200702","article-title":"Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis","volume":"71","author":"Dixon","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2015.08.010_bib37","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/ard.2005.038638","article-title":"Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data","volume":"65","author":"Da Silva","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2015.08.010_bib38","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.21142","article-title":"Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"De Groot","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.rdc.2015.08.010_bib39","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/MD.0000000000000020","article-title":"Granulomatosis with polyangiitis (Wegener's): impact of maintenance therapy duration","volume":"93","author":"Springer","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.rdc.2015.08.010_bib40","first-page":"1017","article-title":"Treatment of subglottic stenosis, due to Wegener\u2019s granulomatosis, with intralesional corticosteroids and dilation","volume":"30","author":"Hoffman","year":"2003","journal-title":"J\u00a0Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2015.08.010_bib41","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1177\/0961203308089693","article-title":"Clinical features and therapeutic management of subglottic stenosis in patients with Wegener\u2019s granulomatosis","volume":"17","author":"Solans-Laqu\u00e9","year":"2008","journal-title":"Lupus"},{"issue":"5","key":"10.1016\/j.rdc.2015.08.010_bib42","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/rheumatology\/kes382","article-title":"Orbital masses in granulomatosis with polyangiitis are associated with a refractory course and a high burden of local damage","volume":"52","author":"Holle","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.rdc.2015.08.010_bib43","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/00002341-199911000-00022","article-title":"Orbital Wegener granulomatosis without systemic findings","volume":"15","author":"Kopstein","year":"1999","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"10","key":"10.1016\/j.rdc.2015.08.010_bib44","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/lary.23949","article-title":"Outcome of a multimodality approach to the management of idiopathic subglottic stenosis","volume":"123","author":"Nouraei","year":"2013","journal-title":"Laryngoscope"},{"key":"10.1016\/j.rdc.2015.08.010_bib45","doi-asserted-by":"crossref","first-page":"w13541","DOI":"10.4414\/smw.2012.13541","article-title":"Vasculitis of the upper airways","volume":"142","author":"Pagnoux","year":"2012","journal-title":"Swiss Med Wkly"},{"issue":"6","key":"10.1016\/j.rdc.2015.08.010_bib46","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/ICU.0b013e32834bdfe2","article-title":"Ocular manifestations of systemic disease: antineutrophil cytoplasmic antibody-associated vasculitis","volume":"22","author":"Schmidt","year":"2011","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.rdc.2015.08.010_bib47","unstructured":"Merkel P. Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis (PEXIVAS)."},{"issue":"2","key":"10.1016\/j.rdc.2015.08.010_bib48","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/BOR.0000000000000145","article-title":"Emerging concepts in the pathogenesis of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"27","author":"Flint","year":"2015","journal-title":"Curr Opin Rheumatol"},{"year":"2000","series-title":"Clinical trial to evaluate safety and efficacy of CCX168 in ANCA-associated vasculitis","author":"ChemoCentryx","key":"10.1016\/j.rdc.2015.08.010_bib49"},{"year":"2000","series-title":"A\u00a0study to evaluate the safety and efficacy of CCX168 in subjects with ANCA-associated vasculitis","author":"ChemoCentryx","key":"10.1016\/j.rdc.2015.08.010_bib50"},{"issue":"8","key":"10.1016\/j.rdc.2015.08.010_bib51","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","article-title":"Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids","volume":"72","author":"Condon","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2015.08.010_bib52","doi-asserted-by":"crossref","first-page":"912562","DOI":"10.1155\/2013\/912562","article-title":"Design of the tocilizumab in giant cell arteritis trial","volume":"2013","author":"Unizony","year":"2013","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.rdc.2015.08.010_bib53","doi-asserted-by":"crossref","first-page":"589841","DOI":"10.1155\/2015\/589841","article-title":"Development and implementation of a double-blind corticosteroid-tapering regimen for a clinical trial","volume":"2015","author":"Collinson","year":"2015","journal-title":"Int J Rheumatol"},{"issue":"11","key":"10.1016\/j.rdc.2015.08.010_bib54","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.38788","article-title":"Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"66","author":"Miloslavsky","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2015.08.010_bib55","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2215\/CJN.07340713","article-title":"Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis","volume":"9","author":"Pendergraft","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.rdc.2015.08.010_bib56","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1002\/art.34584","article-title":"Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener\u2019s): ten-year experience at a single center","volume":"64","author":"Cartin-Ceba","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.rdc.2015.08.010_bib57","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1002\/art.34583","article-title":"Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Smith","year":"2012","journal-title":"Arthritis Rheum"},{"year":"2000","series-title":"Rituximab Vasculitis Maintenance Study (RITAZAREM)","author":"Jayne","key":"10.1016\/j.rdc.2015.08.010_bib58"},{"year":"2000","series-title":"Comparison study of two rituximab regimens in the remission of ANCA associated vasculitis (MAINRITSAN 2)","author":"Assistance Publique \u2013 H\u00f4pitaux de Paris","key":"10.1016\/j.rdc.2015.08.010_bib59"},{"issue":"11","key":"10.1016\/j.rdc.2015.08.010_bib60","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1136\/ard.2009.124958","article-title":"Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice","volume":"69","author":"Van der Goes","year":"2010","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X15000745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X15000745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:14:48Z","timestamp":1760181288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X15000745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0889857X15000745"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2015.08.010","relation":{},"ISSN":["0889-857X"],"issn-type":[{"type":"print","value":"0889-857X"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Corticosteroids in Antineutrophil Cytoplasmic Antibody\u2013Associated Vasculitis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2015.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}